Regulus Therapeutics (NASDAQ:RGLS) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report released on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the company. Wells Fargo & Company boosted their price target on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an equal weight rating in a report on Wednesday, March 13th. Leerink Partnrs reissued an outperform rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. SVB Leerink began coverage on shares of Regulus Therapeutics in a research note on Monday, March 18th. They set an outperform rating and a $6.00 target price on the stock. Canaccord Genuity Group dropped their price target on Regulus Therapeutics from $12.00 to $11.00 and set a buy rating for the company in a research note on Tuesday, March 19th. Finally, HC Wainwright reissued a buy rating and set a $9.00 price objective on shares of Regulus Therapeutics in a report on Monday, March 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $7.25.

Regulus Therapeutics Stock Performance

RGLS opened at $2.13 on Tuesday. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79. The firm has a market cap of $139.43 million, a P/E ratio of -1.34 and a beta of 1.57. The business’s fifty day moving average is $2.13 and its 200-day moving average is $1.60.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). On average, research analysts predict that Regulus Therapeutics will post -0.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its holdings in Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 111,100 shares during the last quarter. Northern Trust Corp raised its stake in Regulus Therapeutics by 42.9% during the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Regulus Therapeutics in the third quarter valued at $54,000. Commonwealth Equity Services LLC boosted its position in Regulus Therapeutics by 52.3% during the third quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 11,500 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Regulus Therapeutics by 108.5% during the 3rd quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 23,738 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.